Severe Disease

Treatment with Paxlovid significantly reduced the duration and severity of SARS-CoV-2 infection among high-risk patients while also reducing health care utilization and severe outcomes, according to a study.

Respiratory syncytial virus vaccines proved highly effective at preventing hospitalization and ED visits in older adults, even in those with immunocompromising conditions, results from an observational analysis showed.

The four core concepts of the CDC’s Social Vulnerability Index could be used to predict the severity of Clostrioides difficile infection and all-cause mortality, according to a study presented at IDWeek.

LOS ANGELES — Paxlovid reduced the risk for severe COVID-19 hospitalization or death among people with existing immunity from a previous infection or vaccination, according to pooled trial data presented at IDWeek.

The human leukocyte antigen DRB1*01:03 allele was associated with severe ulcerative colitis, along with greater odds for major operation, hospitalization and corticosteroid use, according to results of a Danish study.

As older Americans continue to shoulder much of the COVID-19 burden, new data show that most went without a vaccine last winter and that those who got sick rarely received antivirals.

Older adults’ risk for death when hospitalized with respiratory syncytial virus is higher than it is for influenza B but similar to influenza A, according to a study.

CDC advisors this year introduced the idea of transitioning the United States from a universal recommendation for COVID-19 vaccination to a recommendation based on individual risk factors.